University of Colorado

Funded by Biogen, The University of Colorado, and The Global Down Syndrome Foundation, the project will analyze genetics and other biology in 1,000 individuals with the disorder.

The Colorado Center for Personalized Medicine has allied with the tech giant as it begins to integrate genomic and clinical data.

Two new Nature Communications studies underscored the need for better genomic studies of populations of non-European ancestry.

Bison Diversity Boost

Researchers hope to increase the genetic diversity of bison in Minnesota, the Associated Press reports.

A University of Colorado School of Medicine-led team reported 23 new loci associated with vitiligo susceptibility.

The pipeline, called IMPACT, pinpointed genetic variants in lung cancer and melanoma patients and matched them to targeted drugs. 

NEW YORK (GenomeWeb News) — A research team at the University of Colorado, Boulder has received $14.6 million from the Defense Advanced Research Projects Agency to develop a system that will use microfluidics and mass spectrometry to determine how drugs and biological or chemical agents affect hu

NEW YORK (GenomeWeb News) – In a pair of studies online this week in the Proceedings of the National Academy of Sciences, independent research teams presented findings from genome sequencing studies of the Burmese python and king cobra — efforts highlighting the rapid genome changes that

Originally published Oct. 29.

Asuragen of Austin, Texas, has received US Patent No. 8,465,914, "Method and compositions involving microRNA." Methods are claimed for isolating, enriching, and labeling miRNA molecules, and for preparing and using arrays or other detection techniques for miRNA analysis.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.